Large Human Study Offers a Clearer Mechanism Linking Epstein-Barr Virus to Multiple Sclerosis

A long-suspected viral link is becoming biologically clearer

The case against Epstein-Barr virus in multiple sclerosis has been building for years. Now a large new study is helping explain not just whether the virus is involved, but how it may contribute to the disease.

According to New Scientist, researchers led by Yoshiaki Yasumizu at Yale School of Medicine analyzed data from 617,186 people and found evidence that Epstein-Barr virus, or EBV, disrupts immune-cell function in ways that may help trigger multiple sclerosis. The study suggests the virus hijacks B-cells, alters gene expression and activates pathways linked to MS risk.

That matters because EBV infection is extraordinarily common while multiple sclerosis is not. More than 90% of people are infected with the virus at some point, yet only a small minority develop serious long-term complications. The challenge for researchers has been to move from a broad epidemiological association to a biologically credible mechanism. This study appears to push the field in that direction.

Why B-cells are central

The supplied source text emphasizes B-cells as a key target. These immune cells normally produce antibodies that help the body fight infections. But Kate Attfield of the University of Oxford, who was not involved in the study, said the evidence makes clear that EBV resides in B-cells and manipulates them to its own advantage.

That observation fits with what is already known about multiple sclerosis. MS is an autoimmune disease in which the immune system attacks healthy tissue, especially the fatty myelin that insulates neurons. T-cells are heavily involved in the damage seen in the brain and nervous system, but B-cells are increasingly understood to be important players in setting up or sustaining the dysfunctional immune response.

If EBV changes how B-cells behave, it provides a plausible route by which a common infection could increase the risk of an uncommon autoimmune disease in genetically or immunologically susceptible people.

From correlation to mechanism

The broader EBV-MS link is no longer new. The supplied text points back to a 2022 study of 10 million people that found MS was far more likely in people who had been infected with EBV than in those who had not. More recently, a January study identified genetic variants in about one in 10 people that may predispose them to harboring more EBV after infection, while also increasing the risk of MS and other autoimmune conditions.

The new work adds something different: a closer look at the molecular consequences of infection. Rather than merely showing that EBV tends to come before MS, it suggests the virus actively reshapes immune signaling and turns on genes tied to disease vulnerability. That is the kind of evidence researchers need if they hope to move from observational studies to targeted interventions.

Why this could change treatment thinking

Multiple sclerosis affects nearly 2 million people globally and can cause problems with vision, balance, coordination and movement. In some patients it follows a relapsing-remitting pattern; in others it progresses steadily. Current treatments mainly focus on suppressing or redirecting immune activity after the disease process is underway.

If EBV is helping to initiate that process by reprogramming B-cells, then antiviral strategies, vaccines or earlier immune interventions may become more compelling research priorities. The supplied source material does not claim that a preventive therapy is now in hand, and it would be premature to suggest that the mystery of MS has been solved. But the field appears to be moving from “EBV is associated with MS” toward “EBV may directly help create the conditions for MS.”

A complex disease, but a sharper target

MS is unlikely to have a single simple cause. Genetics, immune regulation and environmental triggers all appear to matter. What this study offers is a sharper target within that complexity. By showing how EBV may alter immune cells and activate MS-linked genes, it narrows the gap between infection and disease.

That does not mean every EBV infection is dangerous in the same way, or that the virus alone determines who becomes ill. It does mean the most persistent suspect in MS research now has stronger mechanistic backing. For a disease that has long resisted clear explanation, that is a meaningful shift.

This article is based on reporting by New Scientist. Read the original article.